. During follow-up period (median, 1.2 years), 21 patients died (2-year OS rate, 72%). Patients with elevated GGT showed significantly worse prognosis than those with normal GGT with respective 2-year OS rates of 47% and 87% (P [ 0.002). On multivariate analysis, elevated GGT was a significant and independent factor for shorter OS (hazard ratio, HR [ 4.20; P [ 0.005) as were high PSA (HR [ 5.50; P [ 0.004) and low Hgb (HR [ 4.18; P [ 0.006). Incorporation of GGT into an MSKCC's prognostic model, consisting of age, performance status, Hgb, PSA, LDH, ALP, and albumin, increased its Harrell's c-index from 0.836 to 0.870.
INTRODUCTION AND OBJECTIVES: Discovery of biomarkers could refine treatment of and follow-up programs for men with prostate cancer (PCa). Validation of potential biomarkers for PCa aggressiveness is essential to move biomarkers into clinical use.
Epigenetic modifications of the human genome are important in the development of cancer. We have previously shown that high levels of the epigenetic mark 5-hydroxymethylcytosine (5hmC) in tumor tissue is a significant adverse predictor for biochemical failure (BF) following radical prostatectomy (RP) in patients with ERG negative PCa.
This study aimed to validate the predictive value of 5hmC levels in men undergoing RP for PCa in two independent Danish institutions.
METHODS: The study included 592 PCa patients from two historical RP cohorts (cohort A: RP from 1998 to 2009 at Department of Urology, Aarhus University Hospital, Denmark; cohort B: RP from 2002 to 2005, at Department of Urology, Rigshospitalet, Denmark). 5hmC and ERG protein levels were analyzed using immunohistochemistry (anti-5hmC: 39769, Active Motif; anti-ERG: EPR3864, Epitomics (cohort A) and EPR3864, Roche Ventana (cohort B)) on sections from tissue arrays based on RP specimens. 5hmC levels were dichotomized as low and high based on the predominant staining intensity. ERG expression was categorized as negative or positive. Evaluation of the biomarkers was done blinded.
Risk of BF, defined as PSA ! 0.2ng/ml, was analyzed using cumulative incidences and multiple cause-specific Cox regression. Death without BF was treated as a competing event.
RESULTS: The median time of follow-up after RP was 10.0 years (95% CI: 9.5-10.2). In total, 246 patients (41.6%) had low and 346 patients (58.4%) had high 5hmC levels, whereas 238 patients (40.2%) were ERG negative and 354 patients (59.8%) were ERG positive.
The 10-year cumulative incidence of BF was 47.1% (95% CI: 42.8-51.4). No association between 5hmC or ERG levels and time to BF was found (p[0.2 and p[1.0, respectively). However, for those with ERG negative tumors, the 10-year cumulative incidence of BF was 42.4% (95% CI: 33.6-51.2) in the 5hmC low group compared to 55.4% (95% CI: 45.2-65.6) in the 5hmC high group (p[0.01). Furthermore, in the ERG negative population, multiple cause-specific Cox regression analysis adjusted for age, PSA, pT stage, Gleason score, and margin status showed that high 5hmC level was associated with time to BF (HR: 1.8; 95% CI: 1.2-2.7; p[0.003). CONCLUSIONS: A high 5hmC level is an adverse predictor for BF following RP for patients with ERG negative PCa, which is consistent with previous results.
Source of Funding: The Danish Cancer Society

MP28-13 IDENTIFICATION OF DIFFERENTIALLY EXPRESSED GENES TO PREDICT RADIORESISTANT PROSTATE CARCINOMAS
INTRODUCTION AND OBJECTIVES: Although relapses after radiotherapy are common in prostate cancer (PCa) patients, there are no clinical models or markers to identify patients at high risk for radioresistance. So far, only in vitro studies and xenograft models have been performed to identify gene expression patterns associated with radioresistance. However, studies which address the protein pattern to predict radioresistance in humans are completely missing. In order to determine potential biomarkers for radioresistance, we compared protein expression profiles of radioresistant PCa patients with PCa of primary prostatectomized patients.
METHODS: Two study groups consisting of: I) 30 patients who were treated by salvage prostatectomy and II) 94 patients treated by primary prostatectomy were formed. Tissue microarrays were constructed and immunostained for 15 proteins which are suggested to be associated with radioresistance by in vitro findings. Kruskal-Wallis test was used for multiple group comparison and followed by DunnBonferroni-Test to detect intergroup differences. Cohen's d was used to calculate the intergroup effect size RESULTS: Most proteins studied did not show any relevant differences between radioresistant PCa and primary PCa, except for two (AR and AKR1C3). On comparing immunostaining patterns between radioresistant PCa and primary PCa separated by Gleason risk groups, we observed only AR (androgen receptor) to be most expressed in radioresistant PCa (89.7%) and, in 87.8% of primary PCa of the high-risk group ( > 7a) (p [ 0.851, Cohen's d [ 0.05), while only 67.3% PCa of the low-risk group ( 7a) (p [ 0.017, Cohen's d [ 0.55) 
